



Maryland Situation Update on Coronavirus Disease (COVID-19) for BHA

Maryland Department of Health

Infectious Disease Epidemiology and Outbreak Response Bureau

October 29, 2021

Call Agenda

- Epi summary
- COVID-19 Booster updates
- Q and A

<https://covidlink.maryland.gov/content/vaccine/govax/>




Worldwide: COVID-19

Global Situation


244,897,472

confirmed cases



4,970,435

deaths



Source: World Health Organization

Worldwide: COVID-19

Source: <https://covid19.who.int/> accessed 10/29/21

Situation by Country, Territory or Area



US Case Counts and Rates




<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>

10/29/2021

Number of Cases Reported in the USA, by Day



Daily Trends in Number of COVID-19 Cases in The United States Reported to CDC



Community Transmission


<https://covid.cdc.gov/covid-data-tracker/#county-view>

10/29/2021




Maryland: COVID-19 Cases

- Cases: 559,763
 - 911 new
- Deaths: 10,634
 - 11 new
- Hospitalizations: 50,575
 - Current: 590 (Up 2)
- Case rate: 12.4 per 100,000
- Percent Positivity: 2.41%




Maryland: COVID-19

Source: <https://coronavirus.maryland.gov/>, accessed 10/29/21




Maryland: COVID-19



Source: <https://coronavirus.maryland.gov/>, accessed 10/29/21

Maryland: COVID-19

7 Day Moving Average Case Rate per 100K by Jurisdiction - Full Screen View



Select County

Statewide

10/29/21: **12.5**
per 100k

Low: 6/24/21
at **0.90** per
100K


High: 1/12/21 at
53.39 per 100k

Case Rate per 100K




Maryland: COVID-19

ICU and Acute Hospital Beds for COVID-19, Currently in Use



Hospitalizations, Current

Maryland: COVID-19



US: COVID-19 Vaccinations

Total Vaccine Doses

Delivered 510,735,525

Administered 417,795,537

Learn more about the [distribution of vaccines.](#)

191.2M


People fully vaccinated

15.4M


People received a booster dose**

At Least One Dose	Fully Vaccinated	Booster Dose
Fully Vaccinated* People	Count	Percent of US Population
Total	191,242,432	57.6%
Population ≥ 12 Years of Age	191,109,061	67.4%
Population ≥ 18 Years of Age	178,635,217	69.2%
Population ≥ 65 Years of Age	46,428,087	84.9%

Maryland Vaccine Dashboard



Percent of age groups with at least one dose




US: Delta Variant

<https://covid.cdc.gov/covid-data-tracker/#variant-proportions> Accessed 10/29/21

United States: 7/18/2021 – 10/23/2021

United States: 10/17/2021 – 10/23/2021 NOW




USA				
WHO label	Lineage #	US Class	%Total	95%PI
Alpha	B.1.1.7	VBM	0.0%	0.0-0.0%
Delta	B.1.617.2	VOC	99.5%	99.2-99.8%
	AY.1	VOC	0.1%	0.0-0.1%
	AY.2	VOC	0.0%	0.0-0.0%
Other	Other*		0.4%	0.3-0.8%

* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.
 ** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates
 # Q.1-Q.8 are aggregated with B.1.1.7. AY.3-AY.38 and their sublineages are aggregated with B.1.617.2.

Maryland Influenza Dashboard

<https://health.maryland.gov/phpa/influenza/Pages/flu-dashboard.aspx>
accessed 10/20/21


Clinical Laboratories Influenza Test Percent Positive



Maryland Influenza Dashboard

<https://health.maryland.gov/phpa/influenza/Pages/flu-dashboard.aspx>
accessed 10/27/21

Influenza Associated Hospitalization by Influenza Season



Influenza Associated Hospitalization by Age Group 2021-2022 Influenza Season

Hospitalizations by Age Group (Years)	This Week Count	This Week Percent	Last Week Count	Last Week Percent
0-4	0	0%	0	0%
5-24	1	100%	1	0%
25-49	0	0%	1	0%
50-64	0	0%	1	0%
65+	0	0%	0	0%

COVID-19 Updates

COVID-19 Vaccine Booster Eligibility

- [MDH Bulletin: Updates on Maryland's COVID-19 Vaccine Plan \(10/22/21\)](#)
- [CDC Expands Eligibility for COVID-19 Booster Shots- Media Statement \(10/21/21\)](#)

COVID-19 Vaccine Booster Eligibility

For those individuals that received a primary series of **Pfizer-BioNTech or Moderna COVID-19 vaccine**, all providers shall offer a booster dose of any FDA approved or authorized COVID-19 vaccine at least 6 months after the primary series to the following individuals:

- People 65 years and older
- Age 18+ who live in long-term care settings,
- Age 18+ who have underlying medical conditions,
- Age 18+ who work or live in high-risk settings.

Please note that the dosage for the Moderna booster dose is smaller than the doses in the Moderna primary series.

COVID-19 Vaccine Booster Eligibility

For those individuals that received a primary series of **Janssen (J&J) vaccine**, all providers shall offer a booster dose of any FDA approved or authorized COVID-19 vaccine at least 2 months after the primary dose to any individual 18 years and older.

Patients should talk to their healthcare providers to determine individual benefits and risks of receiving a booster dose.

COVID-19 Vaccine Booster Eligibility

CDC: “There are now booster recommendations for all three available COVID-19 vaccines in the United States. **Eligible individuals may choose which vaccine they receive as a booster dose.**”

Some people may have a preference for the vaccine type that they originally received, and others may prefer to get a different booster. CDC’s recommendations now allow for this type of mix and match dosing for booster shots.”

<https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html>

COVID-19 Vaccines- Hospital Providers

All hospital providers shall, subject to the availability of vaccine supply, offer COVID-19 vaccine to any eligible inpatients being discharged from a hospital admission to a nursing home, assisted living program, or other post-acute care facility (such as a rehabilitation center).

COVID-19 Vaccine- International Travel

- On October 25, 2021, the [CDC issued orders](#) operationalizing the [White House announcement](#) that vaccines will be required for non-U.S. citizens or immigrants traveling to the United States, with an effective date of November 8, 2021.
- For purposes of entry into the United States, vaccines accepted will include FDA approved or authorized and WHO Emergency Use Listing vaccines.

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and ~~During the Period of SARS-CoV-2 B.1.617.2 (Delta)~~ Predominance

- The Delta variant is more transmissible than previously circulating SARS-CoV-2 variants; however, whether it causes more severe disease in adults has been uncertain
- Data from the CDC COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system for COVID-19–associated hospitalizations, were used to examine trends in severe outcomes in adults aged ≥ 18 years hospitalized with laboratory-confirmed COVID-19 during periods before (January–June 2021) and during (July–August 2021) Delta variant predominance

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance

- The proportion of patients who were admitted to an intensive care unit (ICU), received invasive mechanical ventilation (IMV), or died while hospitalized did not significantly change from the pre-Delta period to the Delta period
- When examined by vaccination status, 71.8% of COVID-19–associated hospitalizations in the Delta period were in unvaccinated adults
- During the Delta period, adults aged 18–49 years accounted for a larger proportion of hospitalized patients compared with the pre-Delta period.
- This was driven by the larger number of unvaccinated hospitalized patients in this age group, likely reflecting lower vaccination coverage in younger adults than in older adults.

Questions?

mdh.ipcovid@maryland.gov